AASLD Foundation is proud to announce the new Stravitz Visionary Award! This $500,000 flagship research award is one of the most significant investments in hepatology, marking the largest award in AASLD’s history and in the field.

This new $500,000 award signals a transformative step forward in how AASLD Foundation strategically funds innovation, supports researchers, and shapes the future of hepatology.

AASLD Foundation is proud to announce the new Stravitz Visionary Award! This $500,000 flagship research award is one of the most significant investments in hepatology, marking the largest award in AASLD’s history and in the field.

This new $500,000 award signals a transformative step forward in how AASLD Foundation strategically funds innovation, supports researchers, and shapes the future of hepatology.

Moderators: Christina Awad, MD; Shivaram P Singh, DM, FACG, AGAF, FRCP [Edin]., FAASLD 
Presenters: Shalimar, DM; Rohit Loomba...

Moderators: Ronni Marks; Nitzan Roth, MD, PhD; Elizabeth Goacher, PA-C, MHS, AF-AASLD 
Presenters: Jess Wisocky; Howard Lee, MD...

Presenters review how genomic, trasncriptomic, and other omic technologies can help us understand the causes and inform treatments for MASLD. Experts elaborate on integrative multiomic analyses, genetic subtyping and risk stratification, phenotypic clustering, microbiome analyses, and metabolic and genetic metabolomic profiles as they relate to MASLD.

Speakers delve into the intersections between alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), focusing on how multimorbidity—such as obesity, diabetes, and cardiovascular disease—complicates diagnosis, management, and prognosis. Experts discuss the shared and unique pathophysiological mechanisms, the role of genetic and behavioral risk factors, and the importance of a multidisciplinary approach to patient care.

HCC and other liver nodules can develop in patients with Fontan-associated liver disease (FALD) and other vascular liver diseases, which may include conditions such as heart failure and Budd-Chiari syndrome. Currently, the Liver Imaging Reporting and Data System (LI-RADS)&mdash;a widely used tool for the imaging diagnosis of HCC&mdash;cannot be applied to these patients due to insufficient data and the low specificity of imaging in this context. This session provides an overview of cardiac/vascular liver disease and associated HCC risk. Speakers discuss the controversial topic of HCC surveillance in patients without cirrhosis, explore appropriate surveillance strategies for high-risk patients including those with cirrhosis, and address the diagnostic challenges faced by this population.<br />
<br />
&nbsp;

Clinician educators and those with an interest in medical education are invited to connect with your fellow educators at this meetup. Gather for an hour of informal networking with other TLM attendees pursuing a clinician educator career path to share with colleagues, get and give support, and learn from your peers.